A new trading day began on Tuesday, with Neumora Therapeutics Inc (NASDAQ: NMRA) stock price down -8.67% from the previous day of trading, before settling in for the closing price of $1.00. NMRA’s price has ranged from $0.95 to $17.19 over the past 52 weeks.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
Meanwhile, its annual earnings per share averaged 4.29%. With a float of $56.00 million, this company’s outstanding shares have now reached $161.71 million.
The extent of productivity of a business whose workforce counts for 110 workers is very important to gauge. In terms of profitability, gross margin is 0.0%, operating margin of 0.0%, and the pretax margin is 0.0%.
Neumora Therapeutics Inc (NMRA) Insider and Institutional Ownership
As we move forward, let’s examine how large-scale investors are investing in this stock of the Biotechnology Industry. The insider ownership of Neumora Therapeutics Inc is 65.43%, while institutional ownership is 37.28%. The most recent insider transaction that took place on Mar 12 ’25, was worth 21,450. Before that another transaction happened on Feb 18 ’25, when Company’s insider sold 13,871 for $1.69, making the entire transaction worth $23,468. This insider now owns 7,405,004 shares in total.
Neumora Therapeutics Inc (NMRA) Latest Financial update
Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.4 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around 4.29% per share during the next fiscal year.
Neumora Therapeutics Inc (NASDAQ: NMRA) Trading Performance Indicators
Here are Neumora Therapeutics Inc’s current performance indicators. According to the last quarter’s results, the stock had a quick ratio of 10.51.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -1.53, a number that is poised to hit -0.38 in the next quarter and is forecasted to reach -1.28 in one year’s time.
Technical Analysis of Neumora Therapeutics Inc (NMRA)
The latest stats from [Neumora Therapeutics Inc, NMRA] show that its last 5-days average volume of 1.02 million was inferior to 3.29 million than last year’s volume. As of the previous 9 days, the stock’s Stochastic %D was 8.87%. Additionally, its Average True Range was 0.12.
During the past 100 days, Neumora Therapeutics Inc’s (NMRA) raw stochastic average was set at 0.10%, which indicates a significant decrease from 2.47% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 70.51% in the past 14 days, which was lower than the 275.77% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $1.5749, while its 200-day Moving Average is $8.5985. Now, the first resistance to watch is $0.9822. This is followed by the second major resistance level at $1.0510. The third major resistance level sits at $1.0921. If the price goes on to break the first support level at $0.8723, it is likely to go to the next support level at $0.8312. The third support level lies at $0.7624 if the price breaches the second support level.
Neumora Therapeutics Inc (NASDAQ: NMRA) Key Stats
With a market capitalization of 147.94 million, the company has a total of 161,979K Shares Outstanding. Currently, annual sales are 0 K while annual income is -243,790 K. The company’s previous quarter sales were 0 K while its latest quarter income was -58,820 K.
